State Street SPDR S&P Pharmaceuticals ETF
XPH
71 hedge funds and large institutions have $98.4M invested in State Street SPDR S&P Pharmaceuticals ETF in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 8 closing their positions.
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
0% more funds holding
Funds holding: 71 → 71 (0)
3.58% less ownership
Funds ownership: 56.38% → 52.8% (-3.6%)
7% less capital invested
Capital invested by funds: $105M → $98.4M (-$7.06M)
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
38% less call options, than puts
Call options by funds: $834K | Put options by funds: $1.35M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.32M |
| 2 |
Citigroup
New York
|
+$2.14M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.02M |
| 4 |
GS
GTS Securities
New York
|
+$784K |
| 5 |
Goldman Sachs
New York
|
+$623K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EH
Equitable Holdings
New York
|
-$10.4M |
| 2 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
-$5.92M |
| 3 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$4.28M |
| 4 |
Jane Street
New York
|
-$2.24M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.23M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Two Sigma Investments
New York
| – | -$286K | -7,200 | Closed |
|
|
GLR
77
Great Lakes Retirement
Sandusky,
Ohio
| – | -$57.2K | -1,438 | Closed |
|
|
NRC
78
New Republic Capital
Charlotte,
North Carolina
| – | -$42K | -1,056 | Closed |
|
|
TFF
79
The Family Firm
Bethesda,
Maryland
| – | -$6.79K | -171 | Closed |
|
|
CC
80
Cypress Capital
Franklin,
Tennessee
| – | -$2.25K | -57 | Closed |
|
XPH Hedge Fund Activity: Q3 2024 in Review
71 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2024, worth a combined $98.4M — down 6.7% from $105M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new XPH positions and 8 closed out — a net gain of 1 holder — while 18 added to existing stakes and 24 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $4.32M. The largest seller was Equitable Holdings, exiting entirely with an estimated $10.4M sold.
- 71 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $98.4M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2024, down 6.7% quarter-over-quarter.
- 9 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2024 and 8 closed out, a net change of +1 holder.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2024 was BNP Paribas Financial Markets, an estimated $4.32M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2024 was Equitable Holdings, an estimated $10.4M sold.
Based on aggregated 13F filings for Q3 2024.